Eli Lilly’s Mounjaro sees explosive sales growth, yet demand outpaces supply

Eli Lilly’s diabetes medication Mounjaro (tirzepatide) is seeing explosive sales growth, jumping from $187.3 million in the third quarter of 2022 to $1.4 billion in the same period this year. Conversely, sales of Lilly’s Trulicity, another diabetes drug, have declined, dipping from $1.85 billion in Q3 2022 to $1.67 billion in Q3 2023.

Mounjaro is selling so briskly that Lilly is having trouble making enough of it. The company is aiming to boost supply by recruiting a diverse portfolio of contract manufacturers. It plowed $450 million in its Research Triangle Park facility in North Carolina to support additional drug filling, device assembly, and packaging capacity. It also invested an additional $1.6 billion in new manufacturing sites in its home state of Indiana. Despite the efforts, the company notes that supply problems have led to “intermittent delays” in filling orders and tight supply of the medication throughout most of the third quarter…

Read more
  • 0

Eli Lilly’s obesity focus helps propel promising 2023

2023 is shaping up to be a blockbuster year for Eli Lilly. With the company’s stock soaring by almost 54% since the beginning of the year, analysts are largely upbeat about Lilly’s expanded focus on obesity and diabetes treatments. While the company has developed insulin for a century, the company is now broadening its horizons with Mounjaro (tirzapetide), a diabetes treatment used off-label for obesity. An FDA approval for tirzapatide, a dual GLP-1/GIP receptor agonist, in obesity could occur later this year.

While Lilly has seen its stock surge in 2023 thus far, its performance over the past month hasn’t been as robust — declining by close to 6% over the past month.


“We continue to be pleased with the strong momentum of Mounjaro as more type 2 diabetes patients benefit from the medicine,” said Dave Ricks, chairman and CEO of Eli Lilly, in the company’s second quarter earnings call. In fact, despite ramping up produ…

Read more
  • 0

Lilly’s tirzepatide wins FDA approval for type 2 diabetes

FDA has approved Mounjaro (tirzepatide), the first glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) for treating adults with type 2 diabetes.

Developed by Eli and Co., tirzepatide could quickly become a mega-blockbuster. According to Mizuho Securities, annual sales of the drug could approach $14 billion by 2030.

To win approval, Lilly provided data from the Phase 3 SURPASS clinical studies showing that it supported superior A1C reductions than all comparators, including insulin glargine and insulin degludec. The SURPASS trials also pitted tirzepatide against metformin, SGLT2 inhibitors and sulfonylureas.

The drug also has the side benefit of supporting weight loss, although it is not indicated for obesity. Volunteers in the SURPASS trials lost an average of 12 and 25 lb., depending on dose level.

In the SURMOUNT-1 study, the drug yielded up to 22.5% in adults with obesity or overweight.

Lilly will marke…

Read more
  • 0